Technical Analysis for BGNE - BeiGene, Ltd.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 168.50 | -0.88% | -1.50 |
Earnings due: Mar 27
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Multiple of Ten Bearish | Other | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
NR7 | Range Contraction | -0.88% | |
Inside Day | Range Contraction | -0.88% | |
Gapped Up | Strength | -0.88% | |
Slingshot Bullish | Bullish Swing Setup | -0.24% | |
Multiple of Ten Bearish | Other | -0.24% |
Alert | Time |
---|---|
Possible NR7 | about 17 hours ago |
Possible Inside Day | about 17 hours ago |
Possible NR7 | 4 days ago |
Possible Inside Day | 4 days ago |
Down 1% | 4 days ago |
Get this analysis on your stocks daily!
- Earnings date: 03/27/2024
BeiGene, Ltd. Description
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Monoclonal Antibodies Monoclonal Antibody Lymphoma Oncogenes Protein Kinase Bruton's Tyrosine Kinase Ras Subfamily Recombination Rp1
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 272.39 |
52 Week Low | 132.95 |
Average Volume | 299,455 |
200-Day Moving Average | 183.21 |
50-Day Moving Average | 160.31 |
20-Day Moving Average | 163.88 |
10-Day Moving Average | 165.29 |
Average True Range | 7.81 |
RSI (14) | 54.75 |
ADX | 18.75 |
+DI | 28.62 |
-DI | 19.53 |
Chandelier Exit (Long, 3 ATRs) | 161.38 |
Chandelier Exit (Short, 3 ATRs) | 168.43 |
Upper Bollinger Bands | 180.63 |
Lower Bollinger Band | 147.13 |
Percent B (%b) | 0.64 |
BandWidth | 20.44 |
MACD Line | 3.00 |
MACD Signal Line | 2.17 |
MACD Histogram | 0.8343 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 172.18 | ||||
Resistance 3 (R3) | 172.53 | 171.65 | 171.56 | ||
Resistance 2 (R2) | 171.65 | 170.72 | 171.48 | 171.36 | |
Resistance 1 (R1) | 170.08 | 170.14 | 170.87 | 169.73 | 171.15 |
Pivot Point | 169.20 | 169.20 | 169.60 | 169.03 | 169.20 |
Support 1 (S1) | 167.63 | 168.27 | 168.42 | 167.28 | 165.85 |
Support 2 (S2) | 166.75 | 167.69 | 166.58 | 165.64 | |
Support 3 (S3) | 165.18 | 166.75 | 165.44 | ||
Support 4 (S4) | 164.83 |